Atrium gets FDA clearance for PRKAG2 syndrome trial
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atrium Therapeutics Inc (RNA)
Atrium Therapeutics Inc stock price live, this page displays NASDAQ RNA stock exchange data. View the RNA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Atrium Therapeutics Inc real time stock price chart below.
What Is the Atrium Therapeutics Inc Stock Price Today?
The Atrium Therapeutics Inc stock price today is 11.35.
What Is the Stock Symbol for Atrium Therapeutics Inc?
The stock symbol for Atrium Therapeutics Inc is "RNA."
What Stock Exchange Does Atrium Therapeutics Inc Trade On?
Atrium Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atrium Therapeutics Inc a Good Stock to Buy?
Determining whether Atrium Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNA quote. (ISIN: US04965N1046)
What Is the Atrium Therapeutics Inc Stock Price Today?
The Atrium Therapeutics Inc stock price today is 11.35.
What Is the Stock Symbol for Atrium Therapeutics Inc?
The stock symbol for Atrium Therapeutics Inc is "RNA."
What Stock Exchange Does Atrium Therapeutics Inc Trade On?
Atrium Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atrium Therapeutics Inc a Good Stock to Buy?
Determining whether Atrium Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNA quote. (ISIN: US04965N1046)
NASDAQ
Currency in USD
Fair Value
An estimate of a Atrium Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.20
11.54
52 wk Range
11.13
16.77
RNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Atrium Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.2011.54
52 wk Range
11.1316.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Atrium Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
25.00
Upside
+120.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 10Q Atrium Therapeutics Inc For: 14 May- Investing.com
- Atrium gets FDA clearance for PRKAG2 syndrome trial
- Investing.com
- Form 10Q Atrium Therapeutics Inc For: 14 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.00
(+120.26% Upside)
Earnings
Latest Release
May 14, 2026
EPS / Forecast
-0.97 / --
Revenue / Forecast
19.64M / --
Compare RNA to Peers and Sector
Metrics to compare | RNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −6.9x | −0.4x | |
PEG Ratio | - | 0.00 | 0.00 | |
Price/Book | 0.8x | 0.7x | 2.6x | |
Price / LTM Sales | 5.3x | 9.8x | 3.0x | |
Upside (Analyst Target) | 120.3% | 116.8% | 56.0% | |
Fair Value Upside | Unlock | −3.9% | 9.1% | Unlock |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Atrium Therapeutics (RNA) Stock Price Today?
The Atrium Therapeutics stock price today is 11.35 USD.
What Stock Exchange Does Atrium Therapeutics Trade On?
Atrium Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Atrium Therapeutics?
The stock symbol for Atrium Therapeutics is "RNA."
What Is the Atrium Therapeutics Market Cap?
As of today, Atrium Therapeutics market cap is 194.15M USD.
What Is Atrium Therapeutics's Earnings Per Share (TTM)?
The Atrium Therapeutics EPS (TTM) is -3.43.
When Is the Next Atrium Therapeutics Earnings Date?
Atrium Therapeutics will release its next earnings report on Sep 02, 2026.
From a Technical Analysis Perspective, Is RNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Atrium Therapeutics Stock Split?
Atrium Therapeutics has split 0 times.
What is the current trading status of Atrium Therapeutics (RNA)?
As of Aug 03, 2026, Atrium Therapeutics (RNA) is trading at a price of 11.35 USD, with a previous close of 11.35 USD. The stock has fluctuated within a day range of 11.20 USD to 11.54 USD, while its 52-week range spans from 11.13 USD to 16.77 USD.
What Is Atrium Therapeutics (RNA) Price Target According to Analysts?
The average 12-month price target for Atrium Therapeutics is 25.00 USD, with a high estimate of 25 USD and a low estimate of 25 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +120.26% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.